These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 9371609

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of B-cell epitopes in the envelope glycoproteins of simian immunodeficiency virus.
    Benichou S, Venet A, Beyer C, Tiollais P, Madaule P.
    Virology; 1993 Jun; 194(2):870-4. PubMed ID: 7684879
    [Abstract] [Full Text] [Related]

  • 11. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination.
    McBride BW, Corthals G, Rud E, Kent K, Webster S, Cook N, Cranage MP.
    J Gen Virol; 1993 Jun; 74 ( Pt 6)():1033-41. PubMed ID: 7685372
    [Abstract] [Full Text] [Related]

  • 12. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C, Coulibaly C, Petry H, Voss G, Dittmer U, Bodemer W, Makoschey B, Jurkiewicz E, Lüke W, Hunsmann G.
    AIDS Res Hum Retroviruses; 1994 Jun; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K, Montefiori DC, Mancini M, Rivière Y, Tiollais P, Michel ML.
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [Abstract] [Full Text] [Related]

  • 15. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, Silvestri G, Amara RR, Derdeyn CA.
    Proc Natl Acad Sci U S A; 2015 Aug 25; 112(34):10780-5. PubMed ID: 26261312
    [Abstract] [Full Text] [Related]

  • 16. High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.
    Ita S, Hill AK, Lam EC, Dufort FJ, Yang X, Newman R, Leviyang S, Fofana IB, Johnson WE.
    J Virol; 2018 Apr 01; 92(7):. PubMed ID: 29343575
    [Abstract] [Full Text] [Related]

  • 17. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
    Hulskotte EG, Geretti AM, Siebelink KH, van Amerongen G, Cranage MP, Rud EW, Norley SG, de Vries P, Osterhaus AD.
    J Virol; 1995 Oct 01; 69(10):6289-96. PubMed ID: 7666529
    [Abstract] [Full Text] [Related]

  • 18. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I, Bilska M, Hirsch VM, Montefiori DC.
    J Virol; 2000 Mar 01; 74(6):2960-5. PubMed ID: 10684319
    [Abstract] [Full Text] [Related]

  • 19. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.
    Sugimoto C, Nakayama EE, Shioda T, Villinger F, Ansari AA, Yamamoto N, Suzuki Y, Nagai Y, Mori K.
    J Gen Virol; 2008 Feb 01; 89(Pt 2):554-566. PubMed ID: 18198387
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.